Cannabis Stock Gainers And Losers From February 2, 2022

© Provided by Benzinga

GAINERS:

Item 9 Labs (OTC:INLB) shares closed up 7.14% at $1.20 HEXO (NASDAQ:HEXO) shares closed up 4.62% at $0.67 Next Green Wave Holdings (OTC:NXGWF) shares closed up 3.84% at $0.32

LOSERS:

MGC Pharmaceuticals (OTC:MGCLF) shares closed down -13.83% at $0.02 Green Organic Dutchman (OTC:TGODF) shares closed down -10.57% at $0.10 MedMen Enterprises (OTC:MMNFF) shares closed down -10.49% at $0.14 Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed down -10.28% at $0.42 Greenlane Hldgs (NASDAQ:GNLN) shares closed down -10.16% at $0.71 4Front Ventures (OTC:FFNTF) shares closed down -7.82% at $0.69 C21 Investments (OTC:CXXIF) shares closed down -6.38% at $0.44 22nd Century Group (NASDAQ:XXII) shares closed down -6.33% at $2.07 Charlottes Web Holdings (OTC:CWBHF) shares closed down -6.01% at $1.01 Canopy Gwth (NASDAQ:CGC) shares closed down -5.74% at $8.05 cbdMD (AMEX:YCBD) shares closed down -5.61% at $1.01 GreenTree Hospitality Gr (NYSE:GHG) shares closed down -5.46% at $5.19 GrowGeneration (NASDAQ:GRWG) shares closed down -5.35% at $8.31 OrganiGram Holdings (NASDAQ:OGI) shares closed down -4.97% at $1.53 Village Farms Intl (NASDAQ:VFF) shares closed down -4.82% at $5.13 Aurora Cannabis (NASDAQ:ACB) shares closed down -4.70% at $4.26 ReneSola (NYSE:SOL) shares closed down -4.40% at $5.22 Auxly Cannabis Group (OTC:CBWTF) shares closed down -4.06% at $0.13 BioHarvest Sciences (OTC:CNVCF) shares closed down -4.04% at $0.29 Tilray (NASDAQ:TLRY) shares closed down -3.86% at $5.98 Scotts Miracle Gro (NYSE:SMG) shares closed down -3.67% at $141.31 RIV Capital (OTC:CNPOF) shares closed down -3.64% at $1.06 Marrone Bio Innovations (NASDAQ:MBII) shares closed down -3.43% at $0.69 Cara Therapeutics (NASDAQ:CARA) shares closed down -3.32% at $11.07 Green Thumb Industries (OTC:GTBIF) shares closed down -3.17% at $18.00 Cansortium (OTC:CNTMF) shares closed down -3.11% at $0.61

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.